Literature DB >> 27880664

The current treatment landscape: the need for antifungal stewardship programmes.

Patricia Muñoz1,2,3,4, Emilio Bouza5,2,3,4.   

Abstract

There is increasing evidence supporting the need for antifungal stewardship (AFS) programmes in order to promote appropriate antifungal use, improve diagnosis and quality of care, and decrease the costs of antifungal treatment. AFS programmes delivered by experienced teams can be efficacious and cost effective. However, there are a variety of challenges often faced during the implementation of AFS programmes which can present barriers to their success. These can include lack of dedicated personnel, lack of investment in new diagnostic and prescription tools, and misperception by other physicians.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Mesh:

Substances:

Year:  2016        PMID: 27880664     DOI: 10.1093/jac/dkw391

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  Drug-drug interaction database for safe prescribing of systemic antifungal agents.

Authors:  Saarah Niazi-Ali; Graham T Atherton; Marcin Walczak; David W Denning
Journal:  Ther Adv Infect Dis       Date:  2021-04-30

2.  The Current State of Antifungal Stewardship in Immunocompromised Populations.

Authors:  William Alegria; Payal K Patel
Journal:  J Fungi (Basel)       Date:  2021-04-30

3.  Impact of empirical treatment with antifungal agents on survival of patients with candidemia.

Authors:  R Poves-Alvarez; B Cano-Hernández; M F Muñoz-Moreno; S Balbás-Alvarez; P Román-García; E Gómez-Sánchez; B Martínez-Rafael; E Gómez-Pesquera; M Lorenzo-López; E Alvarez-Fuente; O de la Varga; M Flores; J M Eiros; E Tamayo; M Heredia-Rodríguez
Journal:  Rev Esp Quimioter       Date:  2018-11-30       Impact factor: 1.553

4.  A systematic review of the impact of antifungal stewardship interventions in the United States.

Authors:  Emily Hart; Melanie Nguyen; Meghan Allen; Collin M Clark; David M Jacobs
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-08-21       Impact factor: 3.944

5.  Utility of 1,3 β-d-Glucan Assay for Guidance in Antifungal Stewardship Programs for Oncologic Patients and Solid Organ Transplant Recipients.

Authors:  Marina Machado; Esther Chamorro de Vega; María Del Carmen Martínez-Jiménez; Carmen Guadalupe Rodríguez-González; Antonio Vena; Raquel Navarro; María Isabel Zamora-Cintas; Caroline Agnelli; María Olmedo; Alicia Galar; Jesús Guinea; Ana Fernández-Cruz; Roberto Alonso; Emilio Bouza; Patricia Muñoz; Maricela Valerio
Journal:  J Fungi (Basel)       Date:  2021-01-17

Review 6.  Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?

Authors:  Vasiliki Soulountsi; Theodoros Schizodimos; Serafeim Chrysovalantis Kotoulas
Journal:  Infection       Date:  2021-06-16       Impact factor: 3.553

7.  Impact of antifungal stewardship interventions on the susceptibility of colonized Candida species in pediatric patients with malignancy.

Authors:  Ali Amanati; Parisa Badiee; Hadis Jafarian; Fatemeh Ghasemi; Samane Nematolahi; Sezaneh Haghpanah; Seyedeh Sedigheh Hamzavi
Journal:  Sci Rep       Date:  2021-07-08       Impact factor: 4.379

8.  Searching for a change: The need for increased support for public health and research on fungal diseases.

Authors:  Marcio L Rodrigues; Priscila C Albuquerque
Journal:  PLoS Negl Trop Dis       Date:  2018-06-14

9.  Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients.

Authors:  Jörg Janne Vehreschild; Philipp Koehler; Frédéric Lamoth; Juergen Prattes; Christina Rieger; Bart J A Rijnders; Daniel Teschner
Journal:  Med Mycol       Date:  2021-01-04       Impact factor: 4.076

10. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.